Prospera Financial Services Inc Ascendis Pharma A/S Transaction History

Prospera Financial Services Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 08, 2022	SELL	$78.08 - $117.61 $233,693 - $352,006	-2,993 Closed	0 $0
Q1 2022 May 04, 2022	BUY	$102.18 - $135.75 $105,245 - $139,822	1,030 Added 52.47%	2,993 $351,000
Q4 2021 Feb 10, 2022	SELL	$127.1 - $169.66 $108,797 - $145,228	-856 Reduced 30.37%	1,963 $264,000
Q3 2021 Nov 12, 2021	BUY	$112.67 - $176.92 $50,926 - $79,967	452 Added 19.1%	2,819 $449,000
Q2 2021 Aug 12, 2021	BUY	$121.62 - $145.29 $10,337 - $12,349	85 Added 3.72%	2,367 $311,000
Q1 2021 May 06, 2021	BUY	$124.92 - $173.33 $47,219 - $65,518	378 Added 19.85%	2,282 $294,000
Q4 2020 Feb 12, 2021	SELL	$151.2 - $182.76 $90,568 - $109,473	-599 Reduced 23.93%	1,904 $318,000
Q3 2020 Nov 04, 2020	SELL	$134.29 - $154.32 $11,683 - $13,425	-87 Reduced 3.36%	2,503 $386,000
Q2 2020 Aug 07, 2020	SELL	$110.87 - $156.01 $18,293 - $25,741	-165 Reduced 5.99%	2,590 $383,000
Q1 2020 May 15, 2020	SELL	$97.01 - $145.11 $51,124 - $76,472	-527 Reduced 16.06%	2,755 $310,000
Q4 2019 Feb 12, 2020	BUY	$91.45 - $139.12 $300,138 - $456,591	3,282 New	3,282 $457,000

244

58.8M

250K

377K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.61B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of Prospera Financial Services Inc, based on Form 13F filings with the SEC.

Stay updated on Prospera Financial Services Inc with notifications on news.